BAYER Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €10,250.00 |
| 52 Week High | €23,200.00 |
| 52 Week Low | €9,980.00 |
| Beta | 0.97 |
| 1 Month Change | -1.08% |
| 3 Month Change | -17.39% |
| 1 Year Change | -55.18% |
| 3 Year Change | -49.41% |
| 5 Year Change | -47.48% |
| Change since IPO | -35.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAYER | HU Pharmaceuticals | HU Market | |
|---|---|---|---|
| 7D | -6.4% | -0.4% | -0.9% |
| 1Y | -55.2% | 4.8% | 50.6% |
Return vs Industry: BAYER underperformed the Hungarian Pharmaceuticals industry which returned 5.3% over the past year.
Return vs Market: BAYER underperformed the Hungarian Market which returned 52% over the past year.
Price Volatility
| BAYER volatility | |
|---|---|
| BAYER Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in HU Market | 8.5% |
| 10% least volatile stocks in HU Market | 2.6% |
Stable Share Price: BAYER's share price has been volatile over the past 3 months.
Volatility Over Time: BAYER's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 96,931 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYER fundamental statistics | |
|---|---|
| Market cap | Ft10.06t |
| Earnings (TTM) | -Ft1.15t |
| Revenue (TTM) | Ft18.70t |
0.5x
P/S Ratio-8.7x
P/E RatioIs BAYER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYER income statement (TTM) | |
|---|---|
| Revenue | €47.64b |
| Cost of Revenue | €19.75b |
| Gross Profit | €27.89b |
| Other Expenses | €30.83b |
| Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -2.99 |
| Gross Margin | 58.55% |
| Net Profit Margin | -6.17% |
| Debt/Equity Ratio | 132.3% |
How did BAYER perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield-4%
Payout RatioDoes BAYER pay a reliable dividends?
See BAYER dividend history and benchmarks| Bayer dividend dates | |
|---|---|
| Ex Dividend Date | Apr 29 2024 |
| Dividend Pay Date | May 02 2024 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 13 days |
Does BAYER pay a reliable dividends?
See BAYER dividend history and benchmarks